Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

QNCX

Quince Therapeutics (QNCX)

Quince Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:QNCX
FechaHoraFuenteTítuloSímboloCompañía
13/05/202406:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QNCXQuince Therapeutics Inc
13/05/202406:00Business WireQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
06/05/202415:05Business WireQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
01/04/202406:00Business WireQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
22/02/202406:00Business WireQuince Therapeutics Launches Scientific Advisory BoardNASDAQ:QNCXQuince Therapeutics Inc
15/02/202415:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
15/02/202406:00Business WireQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsNASDAQ:QNCXQuince Therapeutics Inc
07/02/202415:05Business WireQuince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
02/02/202416:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
05/01/202415:01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:QNCXQuince Therapeutics Inc
04/01/202415:05Business WireQuince Therapeutics to Participate at Investor Events in January 2024NASDAQ:QNCXQuince Therapeutics Inc
24/10/202318:34Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
23/10/202306:00Business WireQuince Therapeutics Completes Acquisition of EryDel S.p.A.NASDAQ:QNCXQuince Therapeutics Inc
28/09/202315:53Dow Jones NewsQuince Therapeutics to Advance Study of EryDex as FDA Lifts Application HoldNASDAQ:QNCXQuince Therapeutics Inc
28/09/202315:05Business WireU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaNASDAQ:QNCXQuince Therapeutics Inc
06/09/202306:00Business WireQuince Therapeutics Appoints Dr. Charles S. Ryan as PresidentNASDAQ:QNCXQuince Therapeutics Inc
10/08/202315:05Business WireQuince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023NASDAQ:QNCXQuince Therapeutics Inc
24/07/202316:56Business WireQuince Therapeutics rileva EryDel SpA e il suo asset di fase 3 mirato all'atassia-telangectasia, per cui attualmente non esistono trattamenti approvati, con opportunità stimate per un picco di vendite di oltre 1 miliardo di dollari USANASDAQ:QNCXQuince Therapeutics Inc
24/07/202306:00Business WireQuince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales OpportunityNASDAQ:QNCXQuince Therapeutics Inc
26/05/202316:51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QNCXQuince Therapeutics Inc
25/05/202315:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:QNCXQuince Therapeutics Inc
14/04/202315:13Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:QNCXQuince Therapeutics Inc
14/04/202315:07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:QNCXQuince Therapeutics Inc
11/04/202306:00Business WireQuince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake CapitalNASDAQ:QNCXQuince Therapeutics Inc
06/04/202315:05Business WireQuince Therapeutics Engages MTS Health Partners as Independent Financial AdvisorNASDAQ:QNCXQuince Therapeutics Inc
05/04/202316:16Edgar (US Regulatory)Securities Registration (section 12(b)) (8-a12b)NASDAQ:QNCXQuince Therapeutics Inc
05/04/202315:05Business WireQuince Therapeutics Adopts Limited Duration Stockholders Rights PlanNASDAQ:QNCXQuince Therapeutics Inc
31/03/202315:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:QNCXQuince Therapeutics Inc
22/03/202304:00Business WireQuince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake CapitalNASDAQ:QNCXQuince Therapeutics Inc
21/03/202316:10AllPennyStocks.comAnother Biotech Massively Outperforms Broader EquitiesNASDAQ:QNCXQuince Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:QNCX

Su Consulta Reciente

Delayed Upgrade Clock